• Social media app that harnesses enthusiasm for sports
• Novel marketing campaign with hashtag #WearYourColors
• Investment banking executive joins as financial advisor

FANDOM SPORTS Media Corp. (CSE: FDM) (OTC: FDMSF) (FRANKFURT: TQ42) is doing for sports fans today what the Circus Maximus did for ancient Romans. At this largest of Roman hippodromes (horse racing tracks), some 2,000 feet long and 600 feet wide, spectators were treated to captivating contests that typically featured 12 four-horse chariots racing for four miles as they traversed the Circus’ circumference seven times. The passion and excitement of 250,000 fans, the hippodrome’s seating capacity, as they cheered their favorites on must have made for a deafening din that’s unheard of today. The largest football stadium in America seats just around 100,000. Nevertheless, today’s fans are just as passionate, which is why FANDOM SPORTS, through its social media Android Sports App, is providing a platform for them to express their exuberance and frustration, just as the Circus did for its toga-clad enthusiasts.

Ancient Romans were possessed of the same fervor that might be witnessed at any modern game of football or baseball, which prompted the poet Juvenal to remark that they cared only about ‘bread and circuses’. Other striking similarities exist. Just as today’s sport figures can earn six-figure incomes, another contemporary commentator (the poet, Martial) complained about the huge sums (15 bags of gold) that a winning charioteer might ride off with. The most successful of them all, Diocles, is estimated to have made about 36 million sesterces (about $50 million in today’s money) over the course of his career. So, over a millennium, neither sports fans nor sports seem to have changed much. Our instincts of playfulness and competitiveness appear to go very far back.

Recognizing that basic truth, FANDOM SPORTS has developed the Android Sports Mobile App to give sports fans around the world an uncensored social media platform that will allow them to express their primal, unfiltered passions. The App brings fans together in a very modern setting, the social media environment, which, today, is increasingly rivaling traditional forums of physical interaction. The App is designed to entertain sports enthusiasts with interactive content that offers bragging rights and real-life rewards. True sports addicts will appreciate the App, which allows fans to pick a fight, create their own FanFights or rule over others as they trash talk their way to victory. The FANDOM SPORTS proprietary data centric “argument engine” measures and scores opinionated dialogue, as well as establishing consensus, giving fans and users the ability to dive deeper into one-of-a-kind cultural moments, cheer on favorite sports teams and slam dunk some sweet rewards.

Recently, FANDOM SPORTS launched a new campaign to reward fans who celebrate their teams with creative tattoos and body art. The interactive campaign, with the hashtag #WearYourColors, will identify and reward the most passionate sports fans.  The campaign will kick-off to coincide with the month-long soccer tournament in Russia; it will seek to discover the fans with the most “artistically expressive” tattoos or body art. Winners will get two tickets to any sporting event of their choosing in the U.S. or Canada (http://ibn.fm/dEhqZ).

Additionally, FANDOM SPORTS has engaged the services of Vikas Ranjan, founder and current president of Gravitas Financial Inc., a Toronto-based investment holding and merchant banking firm. Vikas has over 22 years’ experience in diverse areas of finance, capital markets, investments, entrepreneurship and management consulting. His global expertise ranges internationally and includes familiarity with emerging economies, like India, where FANDOM SPORTS expects its App to be well received (http://ibn.fm/sMEpR).

Before co-founding Gravitas Financial, Vikas was the co-founder of Ubika Research, an investment research and capital market services firm. He was also the co-founder of SmallCapPower.com, a leading online portal for small cap investments. His previous experience also includes various management positions with companies such as TAL Global Asset Management and the Bank of Montreal.

For more information, visit the company’s website at www.FANDOMSPORTS.net

• Discovers undervalued real estate investments with the potential for high rate of return
• Economic potential for Montenegro as it partners with NATO and seeks to join the EU
• Investment in two beachside developments in Tivat, Montenegro

American-Swiss Capital, Inc., headquartered in Miami, Florida, is a company focused on seeking quality and undervalued real estate investments to create a high rate of return. The company’s experienced management team possesses the knowledge and skills required to consistently provide accurate and reliable research specifically designed to identify the safest and most profitable investment opportunities. American-Swiss Capital is positioned as a conduit between U.S. equity markets and leading enterprises in Switzerland and Northern Europe. Currently, the company is focused on beachfront property in the small nation of Montenegro.

Montenegro is a tourist destination boasting 45 miles of beaches and drawing in more tourists in 2017 than the total of the country’s population (http://ibn.fm/uT2iI). This tourism has played a large part in the positive gains seen in the last year to the country’s economy. Montenegro is making positive strides as it seeks to join the European Union and further strengthen the country’s economy and reputation. June 4, 2018, marked one year since Montenegro’s accession to NATO.

“Just as Montenegro is stepping up for NATO, NATO is stepping up for Montenegro,” NATO Secretary General Jen Stoltenberg stated during a joint press conference earlier this month. “NATO is a defensive Alliance. We protect all Allies against any threat. So [June 5, 2018], NATO will begin air policing patrols over Montenegro, with jets from Italy and Greece. This peacetime mission will ensure the safety of your skies, whether from civilian or military aircraft in distress, or any other threat. NATO provides this support to Allies without their own air forces – a strong sign of NATO solidarity” (http://ibn.fm/b2y7B).

The world is taking notice of Montenegro, and so is American-Swiss Capital. The company is in negotiations to buy an 18-unit beachfront apartment complex with a private beach and a fixed pontoon boat berth in the Boka Bay community of Tivat, a popular tourist destination. A second project is to construct 30 villas in the Kovac Gated Community directly on Tivat Bay with views of St. Marko Island. American-Swiss Capital sees the potential of a country being noticed by leaders and tourists worldwide.

For more information, visit the company’s website at www.AS-Capital.com

• Lexaria has its patented DehydraTECH™ nutrient infusion technology
• This technology has patent protection for cannabidiol and all other non-psychoactive cannabinoids
• DehydraTECH™ technology provides greater bio-absorption

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is a worldwide leader in enhancing the gastro-intestinal delivery of edible cannabinoid products. The company has its patented nutrient infusion technology called DehydraTECH™. This technology significantly improves the body’s ability to absorb cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, nicotine, drugs, supplements and other beneficial molecules. Lexaria Bioscience is headquartered in Kelowna, British Columbia.

Lexaria has patents granted in the United States and Australia for applications of its DehydraTECH™ technology. In addition, it has numerous patents pending in more than 40 countries. Issued and pending patents name a wide spectrum of lipophilic bioactives and food/carrier particles that can be formulated and delivered using the company’s DehydraTECH™ technology.

The company’s technology has patent protection for cannabidiol and all other non-psychoactive cannabinoids. In December 2017, the company received its first patent from the U.S. Patent Office, which covers nicotine, ibuprofen and aspirin delivery, along with cannabinoids.

In the cannabis business, Lexaria’s focus is to make infused foods taste more like food and less like marijuana, while providing many other benefits.  Fundamentally, the DehydraTECH™ technology makes it possible to transport bioactive substances by way of oral ingestion. DehydraTECH™ does so without the need for inhalational dosing. The technology also enhances the flavor and bouquet of cannabinoid edibles.

A major feature of DehydraTECH™ technology is that dosing doesn’t have to be combined with unhealthy sugars or sweeteners upon administering. Sugars and sweeteners are typically used to mask harsh tastes. The DehydraTECH™ delivery method removes the need for sugar-filled food. DehydraTECH™ features flavor-masking for poor tasting compounds.

The technology also reduces the time of onset of THC (tetrahydrocannabinol) effects. Moreover, it provides greater bio-absorption. Cannabinoids are usually poorly absorbed by the gastrointestinal system. However, Lexaria Biosciences’ DehydraTECH™ increases absorption by five to 10 times, which is equal to that of inhalation. Oral ingestion is also safer than inhalation with devices and involves fewer complexities.

The U.S. National Library of Medicine – National Institutes of Health notes in its article, ‘Inhalation Drug Delivery Devices: Technology Update’, that, “The major problems with the use of inhaler devices are the deposition of aerosolized particles in the oropharyngeal region and upper airways and the lack of coordination between the device activation and inhalation due to lack of patient training” (http://ibn.fm/QqAXW).

The company’s technology also provides protection during stomach transit. Furthermore, DehydraTECH™ bypasses first pass liver effect. The small intestine quickly absorbs LCFAs (Long-Chain Fatty Acids) into the lymphatic system and MCFAs (Medium-Chain Fatty Acids) through the liver.

Recently, Lexaria Bioscience announced lab test results regarding the delivery of nicotine via the gastrointestinal tract and first-rate nicotine absorption in animal blood plasma. The results show rapid speed of onset and bioavailability. These results have led to more and continuing dialogue with foremost nicotine industry participants concerning the possible use of the company’s technology for a smoke-free nicotine outlook. However, Lexaria is not partnering with the tobacco industry.

Lexaria’s DehydraTECH™ technology crosses the intestinal wall very effectively. The company is also studying if it affects blood-brain barrier transmission. If it does, Lexaria says that it has the potential to have major outcomes for biotechnology and pharmaceuticals along with cannabis.

For more information, visit the company’s website at www.LexariaEnergy.com

• PreveCeutical moves on recent stock split to boost share appeal
• Company’s organic therapeutics aim to relieve maladies for patients with diabetes, brain injuries and other conditions
• Alternative medicines market expected to generate nearly $200 billion in revenues by 2025

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) continues working to shore up its share appeal while seeking remedies for a variety of physical ailments through its nature-centric research to help patients with type 2 diabetes and obesity, mild traumatic brain injury, cancer and pervasive pain.

PreveCeutical Medical completed a forward stock split last month on the basis of five new shares per one existing share, which resulted in a corresponding forward split of millions of common share purchase warrants issued following a non-brokered private placement last year (http://ibn.fm/MObzY). The 20.28 million (4.07 million pre-split) common share purchase warrants issued after the June 2017 financing measure allowed holders to buy into the company at a price of $1 per share during the 12 months after the warrants were issued. The expiry date is being extended by an additional 12 months to facilitate their conversion (http://ibn.fm/DPJWn).

The warrant extension will also allow holders to buy shares at a price of $0.20 per share until June 29, 2019. An exception clause allows the company to accelerate the expiration date for exercising the warrants, with 14 business days’ notice, if the closing price of the shares on the Canadian Securities Exchange is at least $0.30 or more for 10 consecutive business days.

“We believe the Stock Split demonstrates the Company’s continued commitment to broaden its shareholder base and we anticipate that the Stock Split will make PreveCeutical’s securities more accessible to investors and enhance liquidity for shareholders,” CEO, president and board chairman Stephen Van Deventer stated in a news release.

PreveCeutical is a company dedicated to providing medical patients with natural and nature-inspired formulations to treat select maladies and help prevent them from occurring. The company has five research and development programs under way and expects to partner with other companies to fund clinical trials once proof of concept has been sufficiently developed (http://ibn.fm/ptWCS).

One area of focus for PreveCeutical has been to make non-psychoactive cannabis product CBD bioavailable to patients through the best means possible, which means enabling it to reach the brain by circumventing the digestive system’s friable processes. Through PreveCeutical’s Sol-gel nasal delivery system, the medication would be able to reach the brain directly through the blood-brain barrier.

The company recently announced that it has signed a non-disclosure agreement with a leading drug delivery device manufacturer to work with the Sol-gels (http://ibn.fm/B2dAg) in preparation for a marketable solution. Earlier this month, PreveCeutical announced an agreement with Stadnyk & Partners to obtain strategic finance and marketing advisory services that will help the company achieve its business growth goals (http://ibn.fm/m9ijw).

PreveCeutical’s drive to develop its Nature Identical line of biopharmaceuticals positions it to take advantage of the mainstreaming of the complementary and alternative medicine market, a sector that’s expected to generate $196.87 billion in revenues by 2025, according to a report by Grand View Research, Inc. (http://ibn.fm/SId04). The market has been driven by the popularity of herbal dietary supplements and other wellness therapies like yoga and acupuncture, but the recent global clamor for legal cannabis-derived products has sparked an explosion in market expectations. Research analyst company Brightfield Group expects the CBD market to reach $1 billion early in the next decade (http://ibn.fm/j1efl). Women’s Marketing, which collaborated with Rodale on original consumer research into the modern “Health and Wellness” consumer mindset, labels wellness “the new black” that has become a status symbol among consumers. The company’s report argues that women in the United States alone invest $40 billion into alternative medicine (http://ibn.fm/k4YQq).

For more information, visit the company’s website at www.PreveCeutical.com

• Equity swap further boosts Pressure BioSciences’ plans to uplist to a major stock exchange later this year
• Latest deal brings total debt-to-equity conversions to over $13.6M in past 30 days
• 2015/2016 debentures, line-of-credit and promissory note, plus various short-term debt, now converted to equity
• Company’s recently acquired Pre-EMT™ platform, allowing for improved protein-based drug development, has significant market potential and adds to a string of technological developments

Pressure BioSciences Inc.’s (OTCQB: PBIO) ambitions to achieve listing on a major stock exchange this year have taken another major step forward as yet another group of debt holders have agreed to a debt-to-equity swap, this time amounting to $7.24 million, representing a strong message of investor support. The total amount of debt that has been converted to equity is now over $13.6 million, all in just the past four weeks (http://ibn.fm/NZQeN).

In a news release, Joseph L. Damasio, the company’s VP of finance and CFO, said, “With today’s announced conversion of an additional $7.24M of debt to equity, total loan debt has been reduced from approximately $16.6M to approximately $3.0M, an amount that we believe is manageable by PBI. We are continuing to talk to the remaining debt holders and have reason to believe that several more may follow the lead of the approximate 40+ debt holders who have converted their debt into equity over the past 30 days. If they do, we believe the amount of loan debt on our Balance Sheet could decrease by an additional 10-20%.”

Jeffrey N. Peterson, chairman of the board of directors, added, “We believe PBI’s recent accomplishments, when combined with the conversion of the majority of our loan debt into equity, will materially enhance our stated objective of uplisting to a national exchange (NASDAQ, NYSE/Amex) later in 2018, which should result in a more stable, attractive, and valuable company for all shareholders.”

This announcement follows a long list of positive news for the company, including first quarter revenue growth and the agreement of an earlier $6.39 million debt-to-equity swap with the company’s 2015/2016 Convertible Debenture Holders, made public on May 18, 2018 (http://ibn.fm/Gyw7s).

Pressure BioSciences develops and produces life sciences laboratory tools based on its pioneering Pressure Cycling Technology (PCT). This patented technology is a powerful instrument that enables scientists to prepare biological samples for use in a wide range of fields, including biomarker discovery, pathology, forensics and agriculture.

The company’s PCT systems, including instruments and related consumables, are in use throughout the U.S., Canada, Europe, Australia, Japan and China, with 300 systems set up in more than 150 labs. The PCT system boasts a number of advantages over other methods, including better DNA detection and improved extraction of cell membrane and other proteins.

Pressure BioSciences is also in collaboration with Phasex Corporation to create water-soluble nanoemulsions, which could have wide-ranging uses in pharmaceutical research and development, cosmetics, food production and various industrial applications (http://ibn.fm/LZ8Hm).

Phasex develops separation processes for extracting various compounds, natural extracts and chemicals using its supercritical fluid (SCF)-based toll processors. By combining Phasex’s extraction methods and PBI’s Ultra Shear Technology (UST) – an innovative technique based on the use of intense shear forces generated by ultra-high pressure – the companies expects to develop stable nanoemulsions that will be of significant commercial interest.

Emulsification refers to the process by which liquids that cannot ordinarily be blended together are held in a mixture, usually with the addition of another chemical, known as a surfactant or an emulsifier. Nanoemulsions allow extremely tiny droplets of one liquid to be mixed with another. Because the droplets are so small, nanoemulsions allow a larger amount of so-called “hydrophobic” liquids to be mixed with water. When used in medicine, this could mean that the nanoparticles are more readily absorbed into the body, resulting in treatments that are more effective. The applications extend beyond medicine to a number of other industries.

With its Ultra Shear Technology, Pressure BioSciences can reduce the need to add surfactants while creating nanoemulsions, which should lead to a purer compound with fewer additives and greater stability.

The company is also optimistic about the market potential of yet another one of its groundbreaking technologies: the Pre-EMT™ platform, which helps pharmaceutical companies create protein-based medicines, and it has already attracted interest from the pharmaceutical industry. Pressure BioSciences acquired Pre-EMT™ when it recently bought all of the assets of BaroFold, Inc., the previous owners of the technology.

Since the acquisition, Pressure BioSciences has entered into a contract with a drug company interested in using Pre-EMT™ to develop protein-based therapeutics, and more deals are in the pipeline (http://ibn.fm/LNNpX).

For more information, visit the company’s website at www.PressureBioSciences.com

• Green is a FinCEN compliant payment processing platform for those in the cannabis industry
• Constant changes within the cannabis industry, as states and the federal government work to define new laws
• SpeedyGrow partnering with local hemp farmers in the Grand Valley to help boost the community’s economy

Medical Cannabis Payment Solutions (OTC: REFG), a financial services company directed at the medical cannabis and banking industries, has been filling the gap for cannabis providers who lack bank support due to federal regulations by providing online banking solutions. First offered only to medical cannabis merchants, the company’s services are now available to the entire cannabis industry through its innovative Green platform. The Green platform allows for electronic payments and secure cash deposits, all while remaining FinCEN compliant. REFG keeps clients in compliance and bears the proof of burden, freeing clients to focus on everything else that goes into running a successful business.

Changes are constantly occurring within the cannabis industry, and REFG stays on top of the changes, making sure that the banking solutions it provides are up-to-date. It is no easy task to stay up-to-date on the changing laws and regulations. Last week, President Trump stated that he was likely to back a marijuana bill to leave the decision of legalization to the states, a remark in direct contrast to the policies backed by Attorney General Jeff Sessions. “It means right now, that for example, in Colorado , and soon in Massachusetts, someone who buys marijuana, someone who sells marijuana is complying with state law, but they are in violation of federal law. And that puts them at risk,” Senator Elizabeth Warren, one of two who introduced the bill, remarked regarding laws as they stand (http://ibn.fm/zX95w). It’s no wonder that traditional banks are hesitant to tackle the unique challenges of this industry as the states and federal government work to define new laws. The Green platform adapts to the changes in compliance, offering the only real solution for cannabis dispensaries who no longer wish to run the risk of operating on a cash-only basis.

While the courts hash out the legalities, REFG has its eyes on the future as it invests in local communities. The CBD extraction facility SpeedyGrow Inc., a subsidiary of REFG, was recently featured on KREX, the CBS-affiliated television station in Grand Junction, Colorado. The news story provides a small tour of the facility and discusses the company’s efforts in CBD extraction. SpeedyGrow is partnering with local hemp farmers every step of the way. During the planting season, the company provides the farmers with Speedy Veg, an organic growth supplement.

After harvesting, farmers no longer need to ship their product four to five hours away to Denver. The full process is now done locally, reducing the cost to farmers which then in turn passes on cost savings to the consumer. The company does not charge farmers for the process of extraction but instead shares the revenue on the back end. The CBD oil is sold in its raw form or turned into products like soft gels or tinctures. “We have embraced being a part of the community and are excited to be a part of a growing segment of the community’s economy,” stated David Schenk, co-owner of Speedy Grow Inc., who sees this process as holding the potential for an economic boom for the area. “We believe this valley can be known for the highest quality CBD anywhere in the nation. That people seek out the flower that’s grown here.” It’s a sentiment that is shared by local farmers (http://ibn.fm/MOIGx).

For more information, visit the company’s website at www.Take.Green

• Strategic planning based off of 125 years of combined experience in the beverage industry
• Significant expected growth in the beverage and cannabis industry as the two join forces
• Multi-phase product to create a distribution platform for domestic and international markets
• Creating a sustainable and successful future that provides quality product worldwide

The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTC: TGODF), a company that produces farm-grown, high quality organic medical cannabis using organic craft growing principles, has announced a global strategic launch into the beverage industry.  The company’s senior management has over 125 years of combined experience in the beverage industry, with international soft drink and beverage alcohol companies in Canada and the United States. They plan to put this experience to work in creating a strategic path into the cannabis beverage market (http://ibn.fm/KdcaL).

Currently, the global beverage industry represents over $1 trillion in sales, according to industry-leading research firm Brightfield Group, and the hemp and CBD category is expected to reach $1 billion by 2020 in the United States. With the beverage industry already accounting for 11 percent of the edible market, the expansion into cannabinoid-infused beverages, such as CBD iced teas, juices and sports drinks, is expected to significantly grow the industry. The company plans to create unique, healthy, organic products for the recreational and medicinal markets while utilizing its expertise through direct investment, joint venture and other strategically suitable opportunities to meet this growing demand. TGOD’s global strategy is twofold. The company will create industry-leading branded products and supply global beverage brands with organic base ingredients. To meet demand and increase product offerings in anticipation of Canada’s legalization of sales to recreational users, TGOD expects to bring its total cannabis production levels to 116,000 kg.

The company is currently developing a 40,000-square-foot state-of-the-art research and development space that includes product development and pilot manufacturing for the beverage industry. This facility is part of a multiple phase project that will foster a first-of-its-kind collaborative environment for joint ventures and partnerships and will become a distribution platform for domestic and international markets in the cannabinoid infused beverage industry. This is part of a multi-phased project located on a 72-acre property in Salaberry-de-Valleyfield, Quebec. The Valleyfield property will feature hybrid facilities with state-of-the-art climate-controlled environment paired with cutting edge automatization technology, including separate zones with independent air handling and environmental systems providing TGOD with optimal growing conditions to produce consistent, high quality organic and pesticide-free cannabis.

TGOD is unique in its approach to the industry. By growing organically (one of only three out of 100+ growers in Canada that does so) and at low costs, the company is creating a product that demands a premium in the market. TGOD has an alliance partnership with Eaton Corp., the second largest power management company in the world that is striving to become a leader in cannabis growing power management and lighting and is doing so by providing TGOD with research and optimization. Through the combined partnerships with Eaton and Ledcor, and operating in power-conscious jurisdictions, the company is positioned to be one of the lowest cost producers in the country. Through strategic partnerships and planning, TGOD is focused on creating a sustainable and successful future that provides quality product worldwide.

For more information, visit the company’s website at www.TGOD.ca

• Sunniva’s Sun-Oil Facility in California will provide Farmacy Phactory with distilled oil products
• Extraction deal is a significant milestone for the company, cements its position as a reliable manufacturer of clean extracted products
• New clinic opened in Windsor, Ontario, via wholly owned subsidiary Natural Health Services

Sunniva Inc. (CSE: SNN) (OTCQX: SNNVF), a vertically integrated medical cannabis provider, has struck an extraction deal with Farmacy Phactory, a family-run California cannabis farm (http://ibn.fm/6ZyUd). Through wholly owned subsidiary CP Logistics, LLC, Sunniva’s Sun-Oil Facility will provide high quality, pure manufactured distilled oil products, including flavored oil formulations for vaporization cartridges. Sunniva will also sell specialized vaporization equipment for use in the therapeutic delivery of the products.

The contract was signed for an initial 12-month term and may be renewed for a further 12 months if Farmacy Phactory elects to do so. Farmacy Phactory is a leading producer of unique high-terpene strains of cannabis, and it is making a name for itself with high-quality products. It combines organic methods with proven traditional techniques to produce a range of exotic strains (http://ibn.fm/w9mhD).

“This is a significant milestone as it establishes Sunniva as a trusted manufacturer of clean, high quality extracted products and reliable hardware to support the vibrant California extraction market place,” Sunniva CEO Dr. Anthony Holler stated in a news release. He explained that the Sun-Oil Facility, which is located one mile from the company’s California Campus in Cathedral City, has a capacity to produce more than 600,000 filled vaporization cartridges a month. The facility is licensed for both volatile and non-volatile extraction, which will allow Sunniva to manufacture different extracted products. The company also has plans to sign more white label contracts with other leading brands in the Golden State, Holler further explained.

“We are pleased to partner with Sunniva to access their manufacturing and product expertise. This agreement is a validation of their large-scale extraction operations and we are excited to bring new products to the California marketplace,” added Mark Greene, president of Farmacy Phactory.

Meanwhile, in Canada, Sunniva’s wholly owned subsidiary, Natural Health Services Ltd., the country’s largest referral network of clinics and trained health professionals, invited members of the public and the press for an open house at its Windsor, Ontario, clinic (http://ibn.fm/yzLjk).

At the clinic’s grand opening celebration on May 30, regional manager Lisa Hogan said that this was the culmination of a long journey and that NHS was excited to be able to provide an important service for the local community (http://ibn.fm/rfcNh).

Speaking to Chris Foord, the host of the Cannabis Show (http://ibn.fm/aPaVl), Hogan said, “We’re going to be focusing on an education-based model of care for our patients that focuses on safe access to medical cannabis: proper education, providing them with the insights of if it’s even a proper product for them, how it can help them, and then, of course, product matching and LP matching and connecting them to those services that will meet their needs.”

The clinic, which is free for patients at the point of use, is now open to take bookings.

With some experts estimating that up to 90 percent of California’s cannabis extracts may be tainted with pesticides, Sunniva’s main goal is to provide safe, cost-effective products. The company operates in the largest cannabis markets in the world – California and Canada, and it aims to become the lowest cost, highest quality cannabis manufacturer in these two markets by providing products that are free of pesticides and building large-scale greenhouses that are compliant with current Good Manufacturing Practices. Through this commitment to detail, Sunniva aims to enable better doctor and patient access to cannabis education and facilitate improved delivery devices for therapeutic purposes.

For more information, visit the company’s website at www.sunniva.com

• Quebec grant will help develop its cannabinoid products; ETST testing will commence in 4Q2018 on formula patents aimed at preventing cancer and other diseases
• ETST will apply for trademark, finalize packaging for debut of medical device designed to diminish sexually transmitted infections; women will be target audience for this product
• Company is focused on developing medical devices for the pharmaceutical and nutraceutical fields and marketing its high-grade line of hemp cannabidiol

Earth Science Tech, Inc. (OTC: ETST) has established testing dates for three of its cannabinoid-based (CBD) products. Funded by a grant from Quebec, ETST is now prototyping three CBD patent formulas. A superfood edible is expected to be ready for 4Q2018. The company is scheduled to begin in vitro testing on its first batch of formulas in the summer of 2019, with a goal of demonstrating the superior antioxidant properties and anti-proliferative effects on breast cancer cells, it announced (http://ibn.fm/egQlU).

The goal of these products is to stop inflammation, maintain quality of life, and help prevent cancer and other degenerative diseases. The branding of these three products is in the planning stage.

ETST, a biotech company based in Doral, Florida, has repositioned its line of full-spectrum CBD offerings. It also conducts R&D for low cost, non-invasive medical devices as it concentrates on manufacturing, marketing and distributing its cannabinoid products to the nutraceutical and pharmaceutical markets.

Its MSN-2 medical device is in its final stage prior to the launch of large-scale marketing. ETST is working with Montreal-based Acceleration, Design et Innovation Inc. to aid in the preparation and introduction. Final packaging is being designed to appeal to its target global audience of women. The device is developed to prevent chlamydia and other sexually transmitted infections.

“The official launch of this medical device is a little like giving birth,” Dr. Michel Aube, CEO and chief science officer of ETST, stated in a news release. “It will be unique in the marketplace and we are branding this device globally. The commercial name will be announced soon, as we are in the process of trademark protection for the logo and name.”

ETST holds several wholly owned subsidiaries. Cannabis Therapeutics is an emerging biotechnology company. KannaBidioiD manufactures and distributes in the recreational sector. Earth Science Foundation, Inc. is becoming a non-profit, accepting grants and donations to conduct additional studies. Earth Science Pharmaceutical develops medical diagnostic tools and vaccines. It also has subsidiary Canno Inno Laboratories Inc., a strategic Montreal, Canada-based company formed to provide ETST with access to government grants.

For more information, visit the company’s website at www.EarthScienceTech.com

• Universal Mobile Interface™ integrates any stream of data onto mobile devices
• CSRH’s first predictive data analytics mobile offering targets 2.5 billion cricket fans
• Supreme Court ruling to benefit growing online gaming market

As a mobile solutions and software development company, Consorteum Holdings, Inc. (OTC: CSRH) is focused on mobile device digital offerings delivery. Consorteum further provides mobile payment solutions and products through its mix of direct offerings, license agreements and joint business agreements. Following a multi-year transition, the company has moved from transaction management with a focus on processing solutions and payment processing alongside financial transaction markets to one that focuses on deepening the company’s commitment to delivering innovative solutions via multiple business verticals (http://ibn.fm/jNNhX).

With its focused efforts on software development and delivery solutions to mobile devices, CSRH enhances delivery of mobile content and mobile payment solutions. With many mobile applications limited by how users are able to interact or by the number of supported devices, CSRH’s key product, its Universal Mobile Interface™ (UMI), provides a state-of-the-art platform that has been designed to integrate any stream of data onto mobile devices, regardless of the operating system. The UMI platform aims to strengthen business verticals with particular focus on fintech management, digital marketing, data storage, cloud utilization, analytics, customer relations management and secure payment processing while providing compliance with regulatory codes (http://ibn.fm/NUNB9).

The company’s UMI technology supports fully regulated, regionally compliant financial and social transactions via mobile and web, enabling the development of a cross operating system to support all mobile devices while satisfying the complex and highly regulated requirements of the mobile fintech sector. The world is on the cusp of a digital communication revolution, and CSRH has strategically positioned itself to help clients bridge the mobile and online divide. Its flagship product, the UMI solution, opens-up opportunities in multiple business verticals in multiple sectors of data analytics, next-gen banking, CRM services, social media, digital marketing and e-commerce. The platform takes care of both the API and the UI aspects of mobile software development, which makes the company’s services truly comprehensive. The UMI solution is extremely flexible, and it can easily be adapted to suit the individual needs of clients. 359 Mobile Inc. has further plans to develop and deploy end-to-end solutions for both cloud and host-based products in the fintech and data analytics industries (http://ibn.fm/DSYwf).

A joint development and distribution agreement between Consorteum Holdings, Inc. and DevLex Ltd. provided the framework for the upcoming release of CSRH’s first predictive data analytics mobile offering with specific focus on the game of cricket, a sport with 2.5 billion fans worldwide (http://ibn.fm/aCVoL). This marked an important milestone in the company’s progress, with the CEO of Consorteum, Craig Fielding, noting in a news release, “An extraordinary amount of work by a dedicated team has gone into not only the technological building of our Predictive Analytics platform, but also into the creation and continual update of the massive statistical database required to support this innovative tool.” Being released by CSRH’s wholly owned subsidiary, 359 Mobile Inc., the company makes further use of its UMI technology for the worldwide distribution of the Predictive Analytics Platform (http://ibn.fm/lA05i).

This cutting-edge predictive analytics tool provides cricket fans with real-time and predictive analytics for deployment to mobile devices with the intent of offering its platform for other sports in the future. A recent article indicates that the move is not only a game-changer for cricket enthusiasts, but the first of many financial technology endeavours for CSRH to capitalize on its fintech focus. This innovative tool requires continual update of a massive statistical database that will soon be in the hands of global cricket fans. A primary target of the UMI platform was to closely work with the interests of sport enthusiast activities online and, subsequently, its mobile gaming industry. With a growing market for online gaming that is predicted to surpass the $1 trillion mark by 2022 (http://ibn.fm/w6yj1), entering the gaming sector strategically positions CSRH for continued growth (http://ibn.fm/lUajX).

A ruling by the Supreme Court on May 14 of this year delivered a states’ rights victory to advocates of sports betting (http://ibn.fm/z7uKK), also notching up wins for companies that have maintained multi-jurisdictional presences for online sports wagers, as well as the companies that supply them with the tech, oversight and marketing services they need to operate (http://ibn.fm/JwP12).

It is with this information in mind that Consorteum aims to promote its state-of-the-art UMI platform that easily lends itself to the delivery of mobile content, along with its suite of mobile offerings and payment solutions.

For more information, visit the company’s website at www.Consorteum.com